Cazzola 1995.

Methods	randomized controlled trial, not placebo‐controlled
Participants	n = 143, multiple myeloma, Non‐Hodgkin lymphoma; concomitant treatment: chemotherapy
Interventions	drug = Epoetin beta dose = a: 1000 IU sc 7x/week, b: 2000 IU sc 7x/week; c: 5000 IU sc 7x/ week; d: 10000 IU sc 7x/week hb‐target = 11‐13 g/dL (MM), 11‐15 g/dL (NHL) planned ESA duration = 8 weeks
Outcomes	Primary: Hb response; secondary: Hb, Hct, reticulocytes, iron, ferritin, safety
Notes	study number = 37653
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	randomization list
Allocation concealment?	Low risk	central randomization